Lineage Cell Therapeutics (LCTX) Equity Average (2016 - 2025)
Historic Equity Average for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to $35.2 million.
- Lineage Cell Therapeutics' Equity Average fell 4651.36% to $35.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.2 million, marking a year-over-year decrease of 4651.36%. This contributed to the annual value of $70.9 million for FY2024, which is 368.68% up from last year.
- Latest data reveals that Lineage Cell Therapeutics reported Equity Average of $35.2 million as of Q3 2025, which was down 4651.36% from $63.7 million recorded in Q2 2025.
- In the past 5 years, Lineage Cell Therapeutics' Equity Average ranged from a high of $122.7 million in Q3 2021 and a low of $35.2 million during Q3 2025
- In the last 5 years, Lineage Cell Therapeutics' Equity Average had a median value of $71.6 million in 2024 and averaged $79.6 million.
- In the last 5 years, Lineage Cell Therapeutics' Equity Average skyrocketed by 2869.15% in 2021 and then tumbled by 4651.36% in 2025.
- Quarter analysis of 5 years shows Lineage Cell Therapeutics' Equity Average stood at $106.5 million in 2021, then fell by 29.14% to $75.4 million in 2022, then fell by 13.79% to $65.0 million in 2023, then increased by 10.07% to $71.6 million in 2024, then tumbled by 50.81% to $35.2 million in 2025.
- Its Equity Average stands at $35.2 million for Q3 2025, versus $63.7 million for Q2 2025 and $78.7 million for Q1 2025.